329 related articles for article (PubMed ID: 19608765)
1. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
Lu X; Wang Q; Hu G; Van Poznak C; Fleisher M; Reiss M; Massagué J; Kang Y
Genes Dev; 2009 Aug; 23(16):1882-94. PubMed ID: 19608765
[TBL] [Abstract][Full Text] [Related]
2. Metalloproteinases and osteoblast EGFR signaling in osteolytic bone metastasis of breast cancer.
Lu X; Kang Y
Cell Cycle; 2009 Dec; 8(23):3804-5. PubMed ID: 19934661
[No Abstract] [Full Text] [Related]
3. Interacting post-muscarinic receptor signaling pathways potentiate matrix metalloproteinase-1 expression and invasion of human colon cancer cells.
Said AH; Hu S; Abutaleb A; Watkins T; Cheng K; Chahdi A; Kuppusamy P; Saxena N; Xie G; Raufman JP
Biochem J; 2017 Feb; 474(5):647-665. PubMed ID: 28008134
[TBL] [Abstract][Full Text] [Related]
4. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases.
Zhu J; Jia X; Xiao G; Kang Y; Partridge NC; Qin L
J Biol Chem; 2007 Sep; 282(37):26656-26665. PubMed ID: 17636266
[TBL] [Abstract][Full Text] [Related]
5. ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression.
Park S; Jung HH; Park YH; Ahn JS; Im YH
Biochem Biophys Res Commun; 2011 Apr; 407(4):680-6. PubMed ID: 21440529
[TBL] [Abstract][Full Text] [Related]
6. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad.
Nickerson NK; Mohammad KS; Gilmore JL; Crismore E; Bruzzaniti A; Guise TA; Foley J
PLoS One; 2012; 7(1):e30255. PubMed ID: 22276166
[TBL] [Abstract][Full Text] [Related]
7. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively.
Liu YJ; Xu Y; Yu Q
Oncogene; 2006 Apr; 25(17):2452-67. PubMed ID: 16314835
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor growth by antibody to ADAMTS1 in mouse xenografts of breast cancer.
Hirano T; Hirose K; Sakurai K; Makishima M; Sasaki K; Amano S
Anticancer Res; 2011 Nov; 31(11):3839-42. PubMed ID: 22110207
[TBL] [Abstract][Full Text] [Related]
9. δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression.
Hu F; Wang C; Guo S; Sun W; Mi D; Gao Y; Zhang J; Zhu T; Yang S
Biochim Biophys Acta; 2011 Mar; 1809(3):200-10. PubMed ID: 21241837
[TBL] [Abstract][Full Text] [Related]
10. Insulin-induced epidermal growth factor activation in vascular smooth muscle cells is ADAM-dependent.
Roztocil E; Nicholl SM; Davies MG
Surgery; 2008 Aug; 144(2):245-51. PubMed ID: 18656632
[TBL] [Abstract][Full Text] [Related]
11. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
[TBL] [Abstract][Full Text] [Related]
13. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
[TBL] [Abstract][Full Text] [Related]
15. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
16. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.
Wang F; Sloss C; Zhang X; Lee SW; Cusack JC
Cancer Res; 2007 Sep; 67(18):8486-93. PubMed ID: 17875687
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.
Guo D; Huang J; Gong J
Mol Cell Biochem; 2012 Apr; 363(1-2):179-90. PubMed ID: 22167620
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases.
Bu G; Lu W; Liu CC; Selander K; Yoneda T; Hall C; Keller ET; Li Y
Int J Cancer; 2008 Sep; 123(5):1034-42. PubMed ID: 18546262
[TBL] [Abstract][Full Text] [Related]
19. Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway.
Taverna S; Pucci M; Giallombardo M; Di Bella MA; Santarpia M; Reclusa P; Gil-Bazo I; Rolfo C; Alessandro R
Sci Rep; 2017 Jun; 7(1):3170. PubMed ID: 28600504
[TBL] [Abstract][Full Text] [Related]
20. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
